Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 5/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522799 | 0.79 | GABRG2 (0.60) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2654854 | 0.74 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL29469733 | 0.73 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL249109 | 0.73 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL341480 | 0.73 | GABRG2 (0.54) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL248720 | 0.72 | GABRG2 (0.57) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL5766441 | 0.72 | GABRG2 (0.66) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL247567 | 0.71 | GABRG2 (0.88) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2759468 | 0.71 | GABRG2 (0.75) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2653692 | 0.70 | GABRA1 (0.40) | GABRG2GABRB3GABRA3GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111895-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2015-04-23 | — | — | US | disclosed |
| US-8921366-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2328414-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130225590-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8399467-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004236-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8003646-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2328414-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010025407-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056529-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004236-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | GABRG2 17/4885GABRB3 7/4885GABRA3 3/4885 |
| US-20150111895-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | GABRG2 17/4885GABRB3 7/4885GABRA3 3/4885 |
| US-20100056529-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | GABRG2 17/4885GABRB3 7/4885GABRA3 3/4885 |
| US-20130225590-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | GABRG2 17/4885GABRB3 7/4885GABRA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.